Drug development orphan diseases
HBM contact: Dr Ivo Staijen, Dr Emil Bujak
Company status: public
Eiger is a clinical-stage company with four programs addressing orphan diseases with a high unmet medical need. Lonafarnib, a Phase 2 stage farnesyl inhibitor is being developed for HDV, the deadliest form of viral hepatitis. Other programs include therapies for hyperinsulinemic hypoglycemia following bariatric surgery, PAH and lymphedema.